Clinical Trial Update: TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

View source ↗

Summary

A real-world, first-line study (TRIMPACT) is currently recruiting to evaluate atezolizumab use in stage IV non-small cell lung cancer with PD-L1 expression ≥50%…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Antalya Training and Research Hospital | Conditions: NSCLC Stage IV, PD-L1 Gene Mutation | Status: RECRUITING